APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine for Human Rabies

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032

29 December 2025119 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine for Human Rabies Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine for Human Rabies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Attenuated Vaccine for Human Rabies include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Attenuated Vaccine for Human Rabies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Attenuated Vaccine for Human Rabies market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Attenuated Vaccine for Human Rabies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Attenuated Vaccine for Human Rabies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Attenuated Vaccine for Human Rabies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Attenuated Vaccine for Human Rabies Market by Company

Changchun Zhuoyi Biological Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

AstraZeneca

Sanofi Pasteur, Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

GlaxoSmithKline

Cadila Pharmaceuticals Ltd

Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell

Human Diploid Cell

Attenuated Vaccine for Human Rabies Segment by Application

Hospital

Clinic

Attenuated Vaccine for Human Rabies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Vero Cell Table 2. Major Company of Human Diploid Cell Table 3. Global Attenuated Vaccine for Human Rabies Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 5. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type (2021-2026) Table 6. Global Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 7. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type (2021-2026) Table 8. Global Attenuated Vaccine for Human Rabies Price by Type (2021-2026) & (US$/Unit) Table 9. Global Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (K Units) Table 10. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type (2027-2032) Table 11. Global Attenuated Vaccine for Human Rabies Sales by Type (2027-2032) & (US$ Million) Table 12. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type (2027-2032) Table 13. Global Attenuated Vaccine for Human Rabies Price by Type (2027-2032) & (US$/Unit) Table 14. North America Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 15. North America Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 17. Europe Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 21. Latin America Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Type (2021-2026) & (US$ Million) Table 24. Attenuated Vaccine for Human Rabies Industry Trends Table 25. Attenuated Vaccine for Human Rabies Industry Drivers Table 26. Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges Table 27. Attenuated Vaccine for Human Rabies Industry Restraints Table 28. Global Attenuated Vaccine for Human Rabies Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Attenuated Vaccine for Human Rabies Revenue Market Share by Company (2021-2026) Table 30. Global Attenuated Vaccine for Human Rabies Sales by Company (2021-2026) & (K Units) Table 31. Global Attenuated Vaccine for Human Rabies Sales Share by Company (2021-2026) Table 32. Global Attenuated Vaccine for Human Rabies Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Attenuated Vaccine for Human Rabies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Attenuated Vaccine for Human Rabies Major Company Production Sites and Headquarters Table 35. Global Attenuated Vaccine for Human Rabies Company, Product Type & Application Table 36. Global Attenuated Vaccine for Human Rabies Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Attenuated Vaccine for Human Rabies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Attenuated Vaccine for Human Rabies Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (K Units) Table 41. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Region (2021-2026) Table 42. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (US$ Million) Table 43. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Region (2021-2026) Table 44. Global Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032) & (K Units) Table 46. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Region (2027-2032) Table 47. Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032) & (US$ Million) Table 48. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Region (2027-2032) Table 49. Global Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Attenuated Vaccine for Human Rabies Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 52. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application (2021-2026) Table 53. Global Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 54. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application (2021-2026) Table 55. Global Attenuated Vaccine for Human Rabies Price by Application (2021-2026) & (US$/Unit) Table 56. Global Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (K Units) Table 57. Global Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application (2027-2032) Table 58. Global Attenuated Vaccine for Human Rabies Sales by Application (2027-2032) & (US$ Million) Table 59. Global Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application (2027-2032) Table 60. Global Attenuated Vaccine for Human Rabies Price by Application (2027-2032) & (US$/Unit) Table 61. North America Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 62. North America Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 64. Europe Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 68. Latin America Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Application (2021-2026) & (US$ Million) Table 71. Changchun Zhuoyi Biological Co., Ltd Company Information Table 72. Changchun Zhuoyi Biological Co., Ltd Business Overview Table 73. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 75. Changchun Zhuoyi Biological Co., Ltd Recent Development Table 76. Wuhan Institute of Biological Products Co., Ltd Company Information Table 77. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 78. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 80. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 81. Shandong Yidu Biotechnology Co., Ltd Company Information Table 82. Shandong Yidu Biotechnology Co., Ltd Business Overview Table 83. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 85. Shandong Yidu Biotechnology Co., Ltd Recent Development Table 86. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information Table 87. Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview Table 88. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 90. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Development Table 91. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information Table 92. Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview Table 93. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 95. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Development Table 96. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 97. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 98. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 100. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 101. Guangzhou Nuocheng Biological Products Co., Ltd Company Information Table 102. Guangzhou Nuocheng Biological Products Co., Ltd Business Overview Table 103. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 105. Guangzhou Nuocheng Biological Products Co., Ltd Recent Development Table 106. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 107. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 108. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 110. Chengdu Kanghua Biological Products Co., Ltd Recent Development Table 111. AstraZeneca Company Information Table 112. AstraZeneca Business Overview Table 113. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio Table 115. AstraZeneca Recent Development Table 116. Sanofi Pasteur, Inc Company Information Table 117. Sanofi Pasteur, Inc Business Overview Table 118. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 120. Sanofi Pasteur, Inc Recent Development Table 121. Pfizer Inc Company Information Table 122. Pfizer Inc Business Overview Table 123. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 125. Pfizer Inc Recent Development Table 126. Novartis AG Company Information Table 127. Novartis AG Business Overview Table 128. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio Table 130. Novartis AG Recent Development Table 131. Merck & Co Inc Company Information Table 132. Merck & Co Inc Business Overview Table 133. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 135. Merck & Co Inc Recent Development Table 136. GlaxoSmithKline Company Information Table 137. GlaxoSmithKline Business Overview Table 138. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio Table 140. GlaxoSmithKline Recent Development Table 141. Cadila Pharmaceuticals Ltd Company Information Table 142. Cadila Pharmaceuticals Ltd Business Overview Table 143. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 145. Cadila Pharmaceuticals Ltd Recent Development Table 146. North America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 148. North America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 149. North America Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032) & (K Units) Table 150. North America Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Country (2027-2032) Table 151. North America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. North America Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026) & (US$ Million) Table 153. North America Attenuated Vaccine for Human Rabies Market Share by Country (2021-2026) Table 154. North America Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. North America Attenuated Vaccine for Human Rabies Market Share Forecast by Country (2027-2032) Table 156. Europe Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 158. Europe Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 159. Europe Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032) & (K Units) Table 160. Europe Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Country (2027-2032) Table 161. Europe Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Europe Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026) & (US$ Million) Table 163. Europe Attenuated Vaccine for Human Rabies Market Share by Country (2021-2026) Table 164. Europe Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Europe Attenuated Vaccine for Human Rabies Market Share Forecast by Country (2027-2032) Table 166. Asia-Pacific Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 168. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 169. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032) & (K Units) Table 170. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Country (2027-2032) Table 171. Asia-Pacific Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Asia-Pacific Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026) & (US$ Million) Table 173. Asia-Pacific Attenuated Vaccine for Human Rabies Market Share by Country (2021-2026) Table 174. Asia-Pacific Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Asia-Pacific Attenuated Vaccine for Human Rabies Market Share Forecast by Country (2027-2032) Table 176. Latin America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Latin America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 178. Latin America Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 179. Latin America Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032) & (K Units) Table 180. Latin America Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Country (2027-2032) Table 181. Latin America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Latin America Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026) & (US$ Million) Table 183. Latin America Attenuated Vaccine for Human Rabies Market Share by Country (2021-2026) Table 184. Latin America Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Latin America Attenuated Vaccine for Human Rabies Market Share Forecast by Country (2027-2032) Table 186. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 187. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 188. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 189. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032) & (K Units) Table 190. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share Forecast by Country (2027-2032) Table 191. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 192. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026) & (US$ Million) Table 193. Middle East and Africa Attenuated Vaccine for Human Rabies Market Share by Country (2021-2026) Table 194. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 195. Middle East and Africa Attenuated Vaccine for Human Rabies Market Share Forecast by Country (2027-2032) Table 196. Key Raw Materials Table 197. Raw Materials Key Suppliers Table 198. Attenuated Vaccine for Human Rabies Distributors List Table 199. Attenuated Vaccine for Human Rabies Customers List Table 200. Research Programs/Design for This Report Table 201. Authors List of This Report Table 202. Secondary Sources Table 203. Primary Sources List of Figures Figure 1. Attenuated Vaccine for Human Rabies Image Figure 2. Global Attenuated Vaccine for Human Rabies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine for Human Rabies Market Size (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine for Human Rabies Sales (2021-2032) & (K Units) Figure 5. Vero Cell Image Figure 6. Global Vero Cell Sales YoY Growth (2021-2032) & (K Units) Figure 7. Human Diploid Cell Image Figure 8. Global Human Diploid Cell Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Attenuated Vaccine for Human Rabies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Attenuated Vaccine for Human Rabies Market Share by Type 2025 VS 2032 Figure 11. North America Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type in 2025 Figure 12. North America Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type in 2025 Figure 13. Europe Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type in 2025 Figure 14. Europe Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type in 2025 Figure 17. Latin America Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinic Image Figure 26. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Attenuated Vaccine for Human Rabies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Attenuated Vaccine for Human Rabies Market Share by Application 2025 VS 2032 Figure 29. North America Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application in 2025 Figure 30. North America Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application in 2025 Figure 31. Europe Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application in 2025 Figure 32. Europe Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application in 2025 Figure 35. Latin America Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Market Share in Value by Application in 2025 Figure 39. North America Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Attenuated Vaccine for Human Rabies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Attenuated Vaccine for Human Rabies Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Attenuated Vaccine for Human Rabies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Attenuated Vaccine for Human Rabies Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Attenuated Vaccine for Human Rabies Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Attenuated Vaccine for Human Rabies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Attenuated Vaccine for Human Rabies Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Attenuated Vaccine for Human Rabies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Attenuated Vaccine for Human Rabies Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Attenuated Vaccine for Human Rabies Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Attenuated Vaccine for Human Rabies Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Vero Cell
  • Human Diploid Cell
Applications
  • Hospital
  • Clinic
Companies covered
  • Changchun Zhuoyi Biological Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shandong Yidu Biotechnology Co., Ltd
  • Ningbo Rongan Biopharmaceutical Co., Ltd
  • Liaoning Yisheng Biopharmaceutical Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Guangzhou Nuocheng Biological Products Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur, Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline
  • Cadila Pharmaceuticals Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Attenuated Vaccine for Human Rabies Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Attenuated Vaccine for Human Rabies Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Attenuated Vaccine for Human Rabies Market by Type
  6. 1.3.1 Vero Cell
  7. 1.3.2 Human Diploid Cell
  8. 1.4 Global Attenuated Vaccine for Human Rabies Market Size by Type
  9. 1.4.1 Global Attenuated Vaccine for Human Rabies Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Attenuated Vaccine for Human Rabies Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Attenuated Vaccine for Human Rabies Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Attenuated Vaccine for Human Rabies Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Attenuated Vaccine for Human Rabies Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Attenuated Vaccine for Human Rabies Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Attenuated Vaccine for Human Rabies Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Attenuated Vaccine for Human Rabies Industry Trends
  2. 2.2 Attenuated Vaccine for Human Rabies Industry Drivers
  3. 2.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine for Human Rabies Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Attenuated Vaccine for Human Rabies Revenue (2021-2026)
  2. 3.2 Global Top Players by Attenuated Vaccine for Human Rabies Sales (2021-2026)
  3. 3.3 Global Top Players by Attenuated Vaccine for Human Rabies Price (2021-2026)
  4. 3.4 Global Attenuated Vaccine for Human Rabies Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Attenuated Vaccine for Human Rabies Major Company Production Sites & Headquarters
  6. 3.6 Global Attenuated Vaccine for Human Rabies Company, Product Type & Application
  7. 3.7 Global Attenuated Vaccine for Human Rabies Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Attenuated Vaccine for Human Rabies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Attenuated Vaccine for Human Rabies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Attenuated Vaccine for Human Rabies Tier 1, Tier 2, and Tier 3
4 Attenuated Vaccine for Human Rabies Regional Status and Outlook
  1. 4.1 Global Attenuated Vaccine for Human Rabies Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Attenuated Vaccine for Human Rabies Historic Market Size by Region
  3. 4.2.1 Global Attenuated Vaccine for Human Rabies Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Attenuated Vaccine for Human Rabies Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Attenuated Vaccine for Human Rabies Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Attenuated Vaccine for Human Rabies Forecasted Market Size by Region
  7. 4.3.1 Global Attenuated Vaccine for Human Rabies Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Attenuated Vaccine for Human Rabies Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Attenuated Vaccine for Human Rabies Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Attenuated Vaccine for Human Rabies by Application
  1. 5.1 Attenuated Vaccine for Human Rabies Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Attenuated Vaccine for Human Rabies Market Size by Application
  5. 5.2.1 Global Attenuated Vaccine for Human Rabies Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Attenuated Vaccine for Human Rabies Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Attenuated Vaccine for Human Rabies Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Attenuated Vaccine for Human Rabies Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Attenuated Vaccine for Human Rabies Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Attenuated Vaccine for Human Rabies Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Attenuated Vaccine for Human Rabies Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Changchun Zhuoyi Biological Co., Ltd
  2. 6.1.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  3. 6.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
  4. 6.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  6. 6.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
  7. 6.2 Wuhan Institute of Biological Products Co., Ltd
  8. 6.2.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  9. 6.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  10. 6.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  12. 6.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  13. 6.3 Shandong Yidu Biotechnology Co., Ltd
  14. 6.3.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  15. 6.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
  16. 6.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  18. 6.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
  19. 6.4 Ningbo Rongan Biopharmaceutical Co., Ltd
  20. 6.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  21. 6.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
  22. 6.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  24. 6.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
  25. 6.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
  26. 6.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
  27. 6.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
  28. 6.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  30. 6.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
  31. 6.6 Lanzhou Institute of Biological Products Co., Ltd
  32. 6.6.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  33. 6.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  34. 6.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  36. 6.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  37. 6.7 Guangzhou Nuocheng Biological Products Co., Ltd
  38. 6.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  39. 6.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
  40. 6.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  42. 6.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
  43. 6.8 Chengdu Kanghua Biological Products Co., Ltd
  44. 6.8.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  45. 6.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  46. 6.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  48. 6.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  49. 6.9 AstraZeneca
  50. 6.9.1 AstraZeneca Company Information
  51. 6.9.2 AstraZeneca Business Overview
  52. 6.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
  54. 6.9.5 AstraZeneca Recent Developments
  55. 6.10 Sanofi Pasteur, Inc
  56. 6.10.1 Sanofi Pasteur, Inc Company Information
  57. 6.10.2 Sanofi Pasteur, Inc Business Overview
  58. 6.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
  60. 6.10.5 Sanofi Pasteur, Inc Recent Developments
  61. 6.11 Pfizer Inc
  62. 6.11.1 Pfizer Inc Company Information
  63. 6.11.2 Pfizer Inc Business Overview
  64. 6.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
  66. 6.11.5 Pfizer Inc Recent Developments
  67. 6.12 Novartis AG
  68. 6.12.1 Novartis AG Company Information
  69. 6.12.2 Novartis AG Business Overview
  70. 6.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
  72. 6.12.5 Novartis AG Recent Developments
  73. 6.13 Merck & Co Inc
  74. 6.13.1 Merck & Co Inc Company Information
  75. 6.13.2 Merck & Co Inc Business Overview
  76. 6.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
  78. 6.13.5 Merck & Co Inc Recent Developments
  79. 6.14 GlaxoSmithKline
  80. 6.14.1 GlaxoSmithKline Company Information
  81. 6.14.2 GlaxoSmithKline Business Overview
  82. 6.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
  84. 6.14.5 GlaxoSmithKline Recent Developments
  85. 6.15 Cadila Pharmaceuticals Ltd
  86. 6.15.1 Cadila Pharmaceuticals Ltd Company Information
  87. 6.15.2 Cadila Pharmaceuticals Ltd Business Overview
  88. 6.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  90. 6.15.5 Cadila Pharmaceuticals Ltd Recent Developments
7 North America by Country
  1. 7.1 North America Attenuated Vaccine for Human Rabies Sales by Country
  2. 7.1.1 North America Attenuated Vaccine for Human Rabies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  4. 7.1.3 North America Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032)
  5. 7.2 North America Attenuated Vaccine for Human Rabies Market Size by Country
  6. 7.2.1 North America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026)
  8. 7.2.3 North America Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Attenuated Vaccine for Human Rabies Sales by Country
  2. 8.1.1 Europe Attenuated Vaccine for Human Rabies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  4. 8.1.3 Europe Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Attenuated Vaccine for Human Rabies Market Size by Country
  6. 8.2.1 Europe Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026)
  8. 8.2.3 Europe Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Country
  2. 9.1.1 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Attenuated Vaccine for Human Rabies Market Size by Country
  6. 9.2.1 Asia-Pacific Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Attenuated Vaccine for Human Rabies Sales by Country
  2. 10.1.1 South America Attenuated Vaccine for Human Rabies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  4. 10.1.3 South America Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032)
  5. 10.2 South America Attenuated Vaccine for Human Rabies Market Size by Country
  6. 10.2.1 South America Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026)
  8. 10.2.3 South America Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country
  2. 11.1.1 Middle East and Africa Attenuated Vaccine for Human Rabies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Attenuated Vaccine for Human Rabies Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country
  6. 11.2.1 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Attenuated Vaccine for Human Rabies Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
  2. 12.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Attenuated Vaccine for Human Rabies Production Mode & Process
  7. 12.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Attenuated Vaccine for Human Rabies Distributors
  10. 12.2.3 Attenuated Vaccine for Human Rabies Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst